Indian Lab Director Calls For Holistic Approach To Drug Research
This article was originally published in PharmAsia News
Drug makers need to adopt a holistic view in conducting research on new pharmaceuticals, according to the director of India's National Chemical Laboratory. In a speech to a drug research conference, Dr. S. Sivaram said most of the drugs considered safe when they were developed have been removed from the market because they did not comply with what science now knows about human biology. He said drug research is about to undergo a huge transformation over the next 50 years with a move into personalized drugs based on genetics. (Click here for more
You may also be interested in...
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
Sun Pharma and its US Taro subsidiary have further criticized a recent CMS policy proposal that would see Medicare Part B drugs approved under the US hybrid 505(b)(2) pathway reimbursed at a lower rate applicable to multiple source products.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.